In the past 5 years, an extensive collaborative effort by biologists, pathologists, and clinicians has resulted in agreement on more stringent criteria for disease diagnosis and for evaluation of clinical response. These efforts support the design of further prospective clinical trials to define the optimal targeted therapeutic approach to NMZL.